Company Overview - ChemoMetec A/S develops, manufactures, and markets instruments for cell counting and various other measurements, targeting the pharmaceutical, biotech, and agricultural industries globally [2] - The company was founded in 1997 and is listed on Nasdaq OMX Copenhagen [2] Managerial Transactions - The company has received a notification regarding transactions related to its shares made by persons in managerial positions, specifically mentioning CEO Martin Helbo Behrens [1]

Core Points - The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025, where the Board of Directors' report and the annual report for 2024/25 were approved [1] - A dividend of DKK 7 per share was approved for distribution [2] - The Board of Directors will continue to consist of 5 members, with Niels Thestrup, Martin Glensbjerg, Kristine Færch, Betina Hagerup, and Peter Reich re-elected [2] - Deloitte was re-elected as the company's auditor, and the remuneration report was approved [3] - The Board of Directors was granted authority to acquire treasury shares [3] - A statutory board meeting was held post-general meeting, re-electing Niels Thestrup as chairman and Martin Glensbjerg as deputy chairman [4] Company Overview - ChemoMetec develops, manufactures, and markets instruments for cell counting and various measurements, serving the pharmaceutical, biotech, and agricultural industries globally [5] - The company was founded in 1997 and is listed on Nasdaq OMX Copenhagen [6]

Core Insights - ChemoMetec has approved its annual report for 2024/25 and provided guidance for the financial year 2025/26, indicating expected revenue and EBITDA growth [1][2] Financial Guidance - For the financial year 2025/26, ChemoMetec anticipates revenue between DKK 545 million and DKK 565 million, compared to DKK 495.6 million in 2024/25, representing an increase of approximately 10% to 14% [1] - The expected EBITDA for 2025/26 is projected to be between DKK 295 million and DKK 315 million, up from DKK 258 million in 2024/25, indicating a growth of around 14% to 22% [1] Company Overview - ChemoMetec specializes in developing, manufacturing, and marketing instruments for cell counting and various other measurements, serving the pharmaceutical, biotech, and agricultural industries globally [3][4] - The company was founded in 1997 and is listed on Nasdaq OMX Copenhagen [4]

Core Viewpoint - ChemoMetec expects to achieve revenue of approximately DKK 496 million for the financial year 2024/25, which is an increase from the previously estimated range of DKK 470-490 million [1]. Company Overview - ChemoMetec develops, manufactures, and markets instruments for cell counting and various other measurements, targeting the pharmaceutical, biotech, and agricultural industries globally [2]. - The company serves some of the world's leading pharmaceutical companies as its customers [2]. - ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen [3].